FONT-SIZE Plus   Neg

Bristol-Myers Squibb, Gladstone Institutes Enter 3-yr Discovery Partnership

Bristol-Myers Squibb Co. (BMY) and the Gladstone Institutes announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.

As per the agreement, Bristol-Myers Squibb will fund Gladstone's research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell's internal skeleton and may help regulate the activity of brain cells.

In Alzheimer's disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
International Business Machines Corp. (IBM) Monday predicted that Cyber Monday online sales would grow by more than 18 percent compared to 2014. Driven by a surge in mobile shopping, consumers indicate that Samsung, Sony and LG TVs as well as Apple Watch and Beats by Dre are at the top of their shopping... As the Black Friday din settles down, it is time to look back at how various players and products fared and Adobe has offered some insight into just that. Mobiles and smartphones sold like hot cakes, according to online shopping data released by Adobe. After nearly a 2-year hiatus following its announcement that it is testing unmanned drones, Amazon finally offered a glimpse into the prototype and its functioning. It remains to be see if the company can work around regulatory hurdles to make it a reality.
comments powered by Disqus
Follow RTT